Go Pro
TSE:CRON

Cronos Group Q3 2025 Earnings Report

Cronos Group logo
C$4.31 -0.10 (-2.27%)
As of 01:59 PM Eastern

Cronos Group EPS Results

Actual EPS
C$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cronos Group Revenue Results

Actual Revenue
$50.60 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cronos Group Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cronos Group Earnings Headlines

TD Forecasts Strong Price Appreciation for Cronos Group (TSE:CRON) Stock
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congressional session, two executive orders signed in a single afternoon, and a quiet government stake in a $20 company have pushed Dylan Jovine to release his most urgent briefing yet. Inside: the day U.S. intelligence has reportedly flagged, a 41-year-old strategy tied to a wave of new millionaires, and growing warnings from the World Economic Forum about a two-tier financial system taking shape.tc pixel
Cronos: Q2 Earnings Snapshot
See More Cronos Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cronos Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cronos Group and other key companies, straight to your email.

About Cronos Group

Cronos Group (TSE:CRON), headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

View Cronos Group Profile